At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Open-Label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor
In Brief
A Phase 2 clinical trial evaluating Erlotinib for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 30 participants across 9 sites.
Detailed Summary
This single arm, open-label study will evaluate the efficacy and safety of erlotinib (Tarceva) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non-Small Cell Lung Cancer
CountriesPortugal
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartMar 2011
Primary CompletionSep 2017
TodayJul 2026
First PostedDec 15, 2010
Enrollment StartMar 31, 2011
Primary CompletionSep 29, 2017
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 15.5 years ago
Interventions
Erlotinibdrug
Erlotinib 150 mg tablet will be given orally daily.